Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.505
-0.015 (-0.43%)
Mar 14, 2025, 9:51 AM EDT - Market open
Iovance Biotherapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -372.18 | -444.04 | -395.89 | -342.25 | -259.58 | |
| Depreciation & Amortization | 43.61 | 33.13 | 21.14 | 13.98 | 8.71 | |
| Loss (Gain) From Sale of Assets | -5.57 | - | - | - | - | |
| Asset Writedown & Restructuring Costs | 7.36 | - | 0.4 | - | - | |
| Loss (Gain) From Sale of Investments | -10.26 | -3.61 | 0.47 | 6.01 | 1.87 | |
| Stock-Based Compensation | 109.63 | 62.63 | 84.02 | 69.77 | 40.89 | |
| Other Operating Activities | -3 | -3.41 | - | - | - | |
| Change in Accounts Receivable | -69.19 | -0.15 | - | - | - | |
| Change in Inventory | -39.92 | -10.12 | - | - | - | |
| Change in Accounts Payable | -7.84 | 4.83 | 5.88 | 6.98 | -2.96 | |
| Change in Other Net Operating Assets | -5.61 | -1.08 | -8.78 | 17.58 | 5.95 | |
| Operating Cash Flow | -352.98 | -361.82 | -292.76 | -227.94 | -205.13 | |
| Capital Expenditures | -11.07 | -22.29 | -20.43 | -37.57 | -46.79 | |
| Cash Acquisitions | -52.57 | -212.63 | - | - | - | |
| Investment in Securities | -32.77 | 79.68 | 276.88 | 37.71 | -271.06 | |
| Investing Cash Flow | -96.41 | -155.24 | 256.46 | 0.13 | -317.85 | |
| Long-Term Debt Issued | - | - | - | 1 | - | |
| Net Debt Issued (Repaid) | - | - | - | 1 | - | |
| Issuance of Common Stock | 403.52 | 465.75 | 192.8 | 238.27 | 576.71 | |
| Repurchase of Common Stock | -12.86 | -2.8 | -2.65 | - | -0.28 | |
| Financing Cash Flow | 390.66 | 462.96 | 190.15 | 239.27 | 576.42 | |
| Foreign Exchange Rate Adjustments | -0.54 | -2.74 | - | - | - | |
| Net Cash Flow | -59.27 | -56.84 | 153.85 | 11.46 | 53.44 | |
| Free Cash Flow | -364.05 | -384.11 | -313.18 | -265.52 | -251.93 | |
| Free Cash Flow Margin | -221.88% | -32305.30% | - | - | - | |
| Free Cash Flow Per Share | -1.26 | -1.63 | -1.97 | -1.73 | -1.82 | |
| Levered Free Cash Flow | -203.22 | -211.47 | -173.54 | -129.35 | -141.4 | |
| Unlevered Free Cash Flow | -203.22 | -211.47 | -173.54 | -129.35 | -141.4 | |
| Change in Net Working Capital | 98.34 | -2.92 | 8.97 | -38.67 | -19.5 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.